US3725429A - Benzamidoimidazolines - Google Patents

Benzamidoimidazolines Download PDF

Info

Publication number
US3725429A
US3725429A US00088978A US3725429DA US3725429A US 3725429 A US3725429 A US 3725429A US 00088978 A US00088978 A US 00088978A US 3725429D A US3725429D A US 3725429DA US 3725429 A US3725429 A US 3725429A
Authority
US
United States
Prior art keywords
percent
filtered
imidazoline
methanol
iodide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US00088978A
Inventor
D Brown
E Watts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beecham Group PLC
Original Assignee
Beecham Group PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beecham Group PLC filed Critical Beecham Group PLC
Application granted granted Critical
Publication of US3725429A publication Critical patent/US3725429A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/30Isothioureas
    • C07C335/38Isothioureas containing any of the groups, X being a hetero atom, Y being any atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44Nitrogen atoms not forming part of a nitro radical
    • C07D233/48Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms

Definitions

  • ABSTRACT lmidazolines having hypotensive and/or anti-inflammatory activity are described. They have the formula:
  • the present invention provides an imidazoline of formula (l) hydrogen, halogen, lower alkyl or lower alkoxy.
  • the terms lower alkyl" and lower alkoxy refer to alkyl and alkoxy groups be chloro-,
  • Compounds of formula (11) may be prepared by reacting an acid chloride (Ill) -c0,ci.
  • the methyla ting agent employed is a methyl halide such as methyl iodide
  • the halide salt e.g. iodide, of compounds (11) is formed directly.
  • One preferred compound of this invention which .on testing in small animals has shown significant hypotensive activity is 2-benzamido-2-imidazoline.
  • One preferred compound which on testing in small animals has shown significant anti-inflammatory activity is 2,4- dichlorobenzamido-2-imidazoline.
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (1) together with conventional liquid or solid pharmaceutical carriers or excipients.
  • the compounds and compositions of this invention' can be administered either orally or parenterally.
  • N-Benzoylthiourea (18.00 g.) was dissolved in the minimum volume of acetone, treated with excess methyl iodide, and allowed to stand at'room temperature overnight. The resulting colorless crystalline. precipitate of N benzoyl-S-methylpseudothiouronium 'iodide (31.00 g.; 97 percent) m.p. 185C. was filtered and washed with cold acetone. (Found: C, 33.97;'H,
  • N-Benzoyl S-methy1pseudothiouronium iodide (1.04 g.) methanol ml.) was added to anhydrous ethylenediamin e.(0.20 g.)'in methanol (5 ml.) and the mixture wa'sallowed .to stand at room temperature.
  • c,,,H,,No requires: c, 63.50; H, 5.82; N, 22.20 percent).
  • N-o-Chlorobenzoylthiourea (4.80 g. was dissolved in the minimum volume of acetone, treated with excess methyl iodide, and allowed to stand at room tempera- .tureovernight.
  • the resulting colorless crystalline precipitate of N-ochlorobenzoyl-S methylpseuidothiouroniumiodide (6.67 g.'; 84 percent) m.p.,l79 C was filtered and. 'washed with coldacetone (Foundzf C 30.27; H, 2.80; N, 7.73; S, 8.87 percent:
  • 614111060 1163 requires: c, 30.30; H, 2.82 N, 7.85; s.
  • N o-Chlorobenzoyl-S-methylpseudothiouronium iodide (6.67 g.) was dissolved in the minimum of methanol, and the solution was added to anhydrous ethylenediamine (0.94 g.) in methanol (12 ml.). The reaction mixture was allowed to stand at room temperature for 3 days. The resulting precipitate was filtered and recrystallizedv from water to give-2 ochlorobenzamido-2-imidazoline (1.94 g.; 24%) as colorless micro-crystals m.p. 228 229C.
  • o-Toluoyl chloride (10.00g.) and thiourea(4.92 g.) were dissolved in toluene,( 1.00 ml.) and heated under reflux for. 18 hours with vigorous stirring. After cooling the resultingprecipitant was filtered andrecrystallized from toluene to give N-o-toluoylthiourea (5.00 g.; 41 percent) as colorless microcrystals m.p. 185C (Found: C, 55.43; H, 5.15; N, 14.39; S, 16.41 percent; C H N OS requires C, 55.62; H, 5.16; N, 14.44, S, 16.50 percent).
  • N-o-Toluoylthiourea (1.94 g.) was dissolved in the minimum volume of acetone treated with excess methyl iodide, and allowed to stand at room temperature'overnight.
  • the resulting colorless precipitant of S- methyl-N-o-toluoylpseudothiouronium iodide (2.24 g.; 66 percent m.p. 157 158C was filtered and washed with cold acetone (Found: C, 35.54; H, 3.86; N, 8.10; S, 9.67 percent; C H IN OS requires: C, 35.70; H, 3.86; N, 8.34; S, 9.52 percent).
  • EXAMPLE 4 p-Anisoyl chloride (17.05 g.) was added dropwise to a suspension of ammonium thiocyanate (7.60 g.) in acetone (50 ml.) at room temperature. The reaction mixture was warmed on a water bath for 5 minutes.
  • N-panisoylthiourea (16.24 g.; 77 percent) as colorless microcrystals m.p. 210 212C (Found: C, 51.44; H, 4.81; N, 13.24; S, 14.08 percent; C H N O S requires: C, 51.12; H, 5.21;N, 13.27;S, 15.16 percent).
  • N-pAnisoylthiourea (8.00 ,g.) was dissolved in the minimum volume of acetone, treated with excess methyl iodide and allowed to stand at room temperature overnight. The resulting precipitant was filtered and washed with cold acetone to give N-p-anisoyl-S- methylpseudothiouronium iodide (9.02 g., 68 percent) as colorless microcrystals m.p. 174 178C. (Found: C, 34.40; H, 3.76; N, 7.84; S, 9.10; l, 36.04 percent; CruHmlNzOgS requires C. 34.50; H. 3.70; N, 7.95; S, 9.09; I, 36.08 percent).
  • N-(2.6-Dimethoxybenzoyl)thiourea (3.57 ,g.) was dissolved in a minimum of dry acetone (350 ml.) and treated with excess methyl iodide (4.35 g.). The reaction mixture was allowed to stand at room temperature for 18 hours and then heated under reflux for half an hour. The resulting crystalline precipitate was filtered and dried in vacuo. Further crops were obtained by evaporation of the mother liquors. The combined precipitates were recrystallized from ethanol ether to yield N-(2-6-dimethoxybenzoyl-S-methylpseudothiouronium iodide) (3.72 g.; 65 percent as colorless microcrystals m.p.
  • N-(2-6-Dimethoxybenzoyl-S-methylpseudothiouronium iodide (4.36 g.) in methanol (30 ml.) was added dropwise at room temperature to anhydrous ethylenediamine (0.69 g.) in methanol (20 ml.) and allowed to stand at room temperature for 7 days.
  • the resulting precipitate was filtered, washed with water (30 ml.) and dried in vacuo to yield 2-6-dimethoxybenzamido-2-imidazoline (1.45 g.; 51 percent) as colorless microcrystals m.p. 264C (Found: C, 57.34; H, 6.05; N, 16.78 percent; C H N D requires C, 57.85; H, 6.03; N, 16.86 percent).
  • N-(2-4-dichlorobenzoyl)thiourea (5.00 g.) was dissolved in a minimum amount of acetone and treated with excess methyl iodide (5.0 g.). The reaction mixture was heated under reflux for 1 hour on a water bath, treated with an equal volume of dry ether and allowed to cool. The resulting precipitate was filtered, washed with dry ,ether and dried in vacuo to give N- (2,4-dichlorobenzoyl)-S-methylpseudothiouroniurn iodide (6.38 g.; percent) as colorless microcrystals m.p. 139C (Found: C, 27.72; H, 2.21; N, 7.16; S, 8.20 percent; C H,Cl IN,OS requires C, 27.60; H, 2.30; N, 7.15;S,8.18 percent).
  • N-(2,4-Dichlorobenzoyl)-S-methylpseudothiouronium iodide (20.00 g.) in methanol (45 ml.) was added to anhydrous ethylenediamine (3.10 g.) in methanol (20 ml.). The reaction mixture was allowed to stand at room temperature for 4 days.
  • N-(2,6-dichloroben-zoyl)thiourea (2.83 g.) was dissolved in dry acetone (25 ml.) and treated with excess methyl iodide (10.0 g.). The resulting solution was percent) as colorless microcrystals m.p.

Abstract

Imidazolines having hypotensive and/or anti-inflammatory activity are described. They have the formula:

WHEREIN R1 and R2 are the same or different and each is hydrogen, halogen, lower alkyl or lower alkoxy. An imidazoline having hypotensive activity is 2-benzamido-2-imidazoline, an anti-inflammatory imidazoline is 2,4-dichlorobenzamido-2imidazoline. The new imidazolines are prepared from et

Description

United States Patent n 1 Brown et al.
[ 5-] Apr. 3, 1973 [541 BENZAMIDOIMIDAZOLINES [75] Inventors: David Maxwell Brown, Dorking; Eric Alfred Watts, Harlow, both of England [73] Assignee: Beecham Group Limited, Brentford,
Middlesex, England [22] Filed: Nov. 12, 1970 21 Ap 1. No.2 88,978
[30] Foreign Application Priority Data Nov. 18, 1969 Great Britain ..56,27l/69 [52] U.S. Cl. ..260/309,6, 260/552 R, 260/558 S,
' 260/559 T, 260/999 [51] Int..Cl. .L ..C07d 49/34 [58] Field of Search ..260/309.6
[56] References Cited OTHER PUBLICATIONS ltoh et a1. Chem. Abst. Vol. 71, No. 8l489g (1969, Oct. 27, i969) QDLASI Musinu .et al. Chem. Abst. .Vol. 70, No. 55930d (1969).QDLA51 Shibata Rubber Chem. Abst. Vol.67, No. 82717j (1967).QD1.A51'
benzamido-Z-imidazoline, an
Primary Examiner-Natalie Trousof AttorneyJacobs & Jacobs [57] ABSTRACT lmidazolines having hypotensive and/or anti-inflammatory activity are described. They have the formula:
R1 N-CHz CONHC I R; N-CHz I 2 Claims, No Drawings BENZAMIDOIMIDAZOLINES v This invention relates to novel imidazoline's which have hypotensive and/or anti-inflammatory activity;
The present inventionprovides an imidazoline of formula (l) hydrogen, halogen, lower alkyl or lower alkoxy. In the present specification the terms lower alkyl" and lower alkoxy refer to alkyl and alkoxy groups be chloro-,
-CON=(f-SCH3 v R: NH: (II) with ethylenediamine.
Compounds of formula (11) may be prepared by reacting an acid chloride (Ill) -c0,ci.
with either (a) ammonium'thiocyanatefollowedby ammonia or (b) thiourea, thereby forming a benzoylthiourea (IV) v I R: (IV) methylating agent. In formulas (11) a (W) R, and R,
have the same significance as in formula '(1').
When the methyla ting agent employed is a methyl halidesuch as methyl iodide, the halide salt e.g. iodide, of compounds (11) is formed directly.
One preferred compound of this invention which .on testing in small animals has shown significant hypotensive activity is 2-benzamido-2-imidazoline. One preferred compound which on testing in small animals has shown significant anti-inflammatory activity is 2,4- dichlorobenzamido-2-imidazoline.
The present invention also provides a pharmaceutical composition comprisinga compound of formula (1) together with conventional liquid or solid pharmaceutical carriers or excipients. The compounds and compositions of this invention'can be administered either orally or parenterally.
The following Examples describe the preparation of I some specific compounds of this invention.
EXAMPLE -1 Benzoyl chloride (28.10 g.) wasaddeddropwise to a suspension of ammonium thiocyanate (15.20 g.) in acetone (1.00 ml) at room temperature. The reaction wherein R and R are the same or different and each is mixture was warmed on a water bath for-5 minutes. Excess 5N ammonium hydroxide solution (500 ml.) was added in one portion and the mixture was heated under reflux for 5 minutes. The resulting solution was poured into distilled water (2 L) to giveN-benzoylthiourea .(26.67 g.; 75 percent) as colorless microcrystals, m.p.
N-Benzoylthiourea (18.00 g.) was dissolved in the minimum volume of acetone, treated with excess methyl iodide, and allowed to stand at'room temperature overnight. The resulting colorless crystalline. precipitate of N benzoyl-S-methylpseudothiouronium 'iodide (31.00 g.; 97 percent) m.p. 185C. was filtered and washed with cold acetone. (Found: C, 33.97;'H,
3.48; N 8.68; S,- 9.77 percent; C H IN,OS requires: C, 33.55;H,3.4l;N,8.70;S,9.94 percent).
N-Benzoyl S-methy1pseudothiouronium iodide (1.04 g.) methanol ml.) was added to anhydrous ethylenediamin e.(0.20 g.)'in methanol (5 ml.) and the mixture wa'sallowed .to stand at room temperature.
After 7 days the resulting colorless needles of 2- '-benzamido-2'-imidazoline (0.48 g.; 78 percent) m.p.
(III) Q j-chlorobenzoylthiourea (6.74 g.; 31 percent) m.p. 164
' 165C. (Found: C,,44. 80; H, 3.24;-N, 13.10; S, 14.95;
I and then reacting said benzoylthiourea (IV) with a 184" 7 187C were filtered and washed with methanol (10 ml.). (Found: C, 63.29; H, 5.92;'N, 22.24 percent;
c,,,H,,No requires: c, 63.50; H, 5.82; N, 22.20 percent)..
I EXAMPLE 2 o-Chlorobenzoyl chloride (17.50 g.) and thiourea (7.60 g.) were dissolved in toluene ml.) and heated underreflux for 18hours with-vigorous stirring. After cooling the resulting precipitate was filtered and recrystallized from toluene to give v N-o- Cl,16.53 percent; C H-,ClN,OS requires: C, 44.75; H,
' 3.26;N, 13.25; S, 14.80, Cl, 16.32 percent).
N-o-Chlorobenzoylthiourea (4.80 g. was dissolved in the minimum volume of acetone, treated with excess methyl iodide, and allowed to stand at room tempera- .tureovernight. The resulting colorless crystalline precipitate of N-ochlorobenzoyl-S methylpseuidothiouroniumiodide (6.67 g.'; 84 percent) m.p.,l79 C was filtered and. 'washed with coldacetone (Foundzf C 30.27; H, 2.80; N, 7.73; S, 8.87 percent:
614111060 1163 requires: c, 30.30; H, 2.82 N, 7.85; s.
8.98 percent).
N o-Chlorobenzoyl-S-methylpseudothiouronium iodide (6.67 g.) was dissolved in the minimum of methanol, and the solution was added to anhydrous ethylenediamine (0.94 g.) in methanol (12 ml.). The reaction mixture was allowed to stand at room temperature for 3 days. The resulting precipitate was filtered and recrystallizedv from water to give-2 ochlorobenzamido-2-imidazoline (1.94 g.; 24%) as colorless micro-crystals m.p. 228 229C.
(Found: C, 53.43; H, 4.59; N, 18.59;.Cl, 15.93 percent; 'c,,H,,,c|N,o requires: c, 53.75; H, 4.48; N,
o-Toluoyl chloride (10.00g.) and thiourea(4.92 g.) were dissolved in toluene,( 1.00 ml.) and heated under reflux for. 18 hours with vigorous stirring. After cooling the resultingprecipitant was filtered andrecrystallized from toluene to give N-o-toluoylthiourea (5.00 g.; 41 percent) as colorless microcrystals m.p. 185C (Found: C, 55.43; H, 5.15; N, 14.39; S, 16.41 percent; C H N OS requires C, 55.62; H, 5.16; N, 14.44, S, 16.50 percent).
N-o-Toluoylthiourea (1.94 g.) was dissolved in the minimum volume of acetone treated with excess methyl iodide, and allowed to stand at room temperature'overnight. The resulting colorless precipitant of S- methyl-N-o-toluoylpseudothiouronium iodide (2.24 g.; 66 percent m.p. 157 158C was filtered and washed with cold acetone (Found: C, 35.54; H, 3.86; N, 8.10; S, 9.67 percent; C H IN OS requires: C, 35.70; H, 3.86; N, 8.34; S, 9.52 percent).
S-Methyl-N-o-toluoylpseudothiouronium iodide (7.58 g.) in methanol (20 ml.) was added to anhydrous ethylenediamine (1.35 g) in methanol ml.). The resulting solution was heated under reflux for 1 hour and was then allowed to cool and stand at room temperature for 3 days. The resulting crystalline precipitate was filtered and recrystallized from aqueous g.). The reaction mixture was warmed on a water bath for 5 minutes. Excess 5N ammonium hydroxide (7 ml.) was added dropwise and the mixture was heated under reflux for a further 5 minutes. The reaction mixture was then poured into distilled water (600 ml.). The result ing crystalline precipitate was filtered, dried in vacuo and recrystallized from toluene to give N-(2-6- dimethoxybenzoyl)thiourea (1.84 g.; 31 percent) as pale yellow microcrystals m.p. 236 238C (Found: C, 50.10; H, 5.03; N, 11.49; S,13.58 percent; C H N O S requires: C, 50.00; H, 5.00; N, 11.68; S, 13.32 permethanol to give 2-o-toluamido-2-imidazoline (1.41 g.;
35 percent as colorless microcrystals m.p. 158 159C (Found: C, 65.02; H, 6.42; N, 20.04 percent; C H N 0 requires: C, 65.00; H, 6.40; N, 20.68 percent).
EXAMPLE 4 p-Anisoyl chloride (17.05 g.) was added dropwise to a suspension of ammonium thiocyanate (7.60 g.) in acetone (50 ml.) at room temperature. The reaction mixture was warmed on a water bath for 5 minutes.
Excess 5N ammonium hydroxide solution (90 ml.) was added in one portion and the mixture was heated under reflux for 5 minutes. The resulting solution was poured into distilled water (1L) to give N-panisoylthiourea (16.24 g.; 77 percent) as colorless microcrystals m.p. 210 212C (Found: C, 51.44; H, 4.81; N, 13.24; S, 14.08 percent; C H N O S requires: C, 51.12; H, 5.21;N, 13.27;S, 15.16 percent).
N-pAnisoylthiourea (8.00 ,g.) was dissolved in the minimum volume of acetone, treated with excess methyl iodide and allowed to stand at room temperature overnight. The resulting precipitant was filtered and washed with cold acetone to give N-p-anisoyl-S- methylpseudothiouronium iodide (9.02 g., 68 percent) as colorless microcrystals m.p. 174 178C. (Found: C, 34.40; H, 3.76; N, 7.84; S, 9.10; l, 36.04 percent; CruHmlNzOgS requires C. 34.50; H. 3.70; N, 7.95; S, 9.09; I, 36.08 percent).
A suspension of N-p-anisoyl-S-methylpseudothiouronium iodide (9.09 g.) in methanol (50 ml.) was added to anhydrous ethylenediamine (1.54 g.) in methanol (10 ml.) and the resulting clear solution allowed to stand at room temperature for 3 days. Addition of water (100 ml.) yielded a colorless precipitate which was filtered and recrystallized from water to give 2-p-anisamido-Z-imidazoline (0.93 g.; 17%) as paleyellow microcrystals m.p. 172 174C (Found: C, 60.28; H, 6.03; N, 19.25 percent; C,,H,,N,0, requires: C, 60.25; H,5.93; N, 19.18 percent.
EXAMPLE 5 2-5-Dimethoxybenzoyl chloride (4.75 g.) was dissolved in a minimum amount of acetone and added dropwise to a solution of ammonium thiocyanate (1.81
N-(2.6-Dimethoxybenzoyl)thiourea (3.57 ,g.) was dissolved in a minimum of dry acetone (350 ml.) and treated with excess methyl iodide (4.35 g.). The reaction mixture was allowed to stand at room temperature for 18 hours and then heated under reflux for half an hour. The resulting crystalline precipitate was filtered and dried in vacuo. Further crops were obtained by evaporation of the mother liquors. The combined precipitates were recrystallized from ethanol ether to yield N-(2-6-dimethoxybenzoyl-S-methylpseudothiouronium iodide) (3.72 g.; 65 percent as colorless microcrystals m.p. 178-182C (Found: C, 34.65; H, 3.98; N, 7.25; S, 8.39; l, 33.37 percent; C,,H, 1N O S requires, C, 34.60; H, 3.93; N, 7.35; S, 8.40; I, 33.80 percent).
N-(2-6-Dimethoxybenzoyl-S-methylpseudothiouronium iodide (4.36 g.) in methanol (30 ml.) was added dropwise at room temperature to anhydrous ethylenediamine (0.69 g.) in methanol (20 ml.) and allowed to stand at room temperature for 7 days. The resulting precipitate was filtered, washed with water (30 ml.) and dried in vacuo to yield 2-6-dimethoxybenzamido-2-imidazoline (1.45 g.; 51 percent) as colorless microcrystals m.p. 264C (Found: C, 57.34; H, 6.05; N, 16.78 percent; C H N D requires C, 57.85; H, 6.03; N, 16.86 percent).
EXAMPLE 6 N-(2-4-dichlorobenzoyl)thiourea (5.00 g.) was dissolved in a minimum amount of acetone and treated with excess methyl iodide (5.0 g.). The reaction mixture was heated under reflux for 1 hour on a water bath, treated with an equal volume of dry ether and allowed to cool. The resulting precipitate was filtered, washed with dry ,ether and dried in vacuo to give N- (2,4-dichlorobenzoyl)-S-methylpseudothiouroniurn iodide (6.38 g.; percent) as colorless microcrystals m.p. 139C (Found: C, 27.72; H, 2.21; N, 7.16; S, 8.20 percent; C H,Cl IN,OS requires C, 27.60; H, 2.30; N, 7.15;S,8.18 percent).
N-(2,4-Dichlorobenzoyl)-S-methylpseudothiouronium iodide (20.00 g.) in methanol (45 ml.) was added to anhydrous ethylenediamine (3.10 g.) in methanol (20 ml.). The reaction mixture was allowed to stand at room temperature for 4 days. The resulting precipitate was filtered, washed with methanol and water and dried in vacuo to give 2,4-dichlorobenzamido-2-imidazoline (8.67 g.; 66 229 231C (Found: C, 46.58; H, 3.44; N, 16.36; Cl, 27.45 percent; C H Cl N O requires C, 46.42; H, 3.49; N, 16.26; Cl, 27.52 percent).
EXAMPLE 7 2-6-Dichlorobenzoyl chloride (5.0 g.) and thiourea (1.81 g.) were dissolved in toluene (100 ml.) and heated under reflux with stirring for 48 hours. The hot solution was filtered and allowed to cool. The resulting precipitate was filtered, washed with toluene and dried in vacuo to give N-(2,6-dichlorobenzoyl)thiourea (2.56 g.; 43 percent) as paleyellow microcrystals m.p. 220 222C (Found: C, 38.60; H, 2.36;, N, 11.09; S,
12.89 percent; C H Cl N OS requires C, 38.70; H.
2.41; N, 11.25; S, 12.85 percent).
N-(2,6-dichloroben-zoyl)thiourea (2.83 g.) was dissolved in dry acetone (25 ml.) and treated with excess methyl iodide (10.0 g.). The resulting solution was percent) as colorless microcrystals m.p.
heated under reflux for 2 hours. Thereaction mixture was then concentrated in vacuo to about 5 ml. and treated with dry ether. The supernatant liquors were decanted from the resulting gum, which was dissolved in methanol (30 ml.). This methanolic solution of crude N-(2,6-dichlorobenzoyl)-S-methylpseudothiouronium iodide was added dropwise to a solution of ethylenediamine(0.69 g.) in methanol (5 ml.) at room temperature. The resulting crystalline precipitate (2.08 g was filtered, washed with a little methanol and dried in vacuo. Recrystallization from dimethyl' sulphoxide/water followed by filtration through a column of silica gel G with chloroform as eluent and finally recrystallization from dimethyl sulphox'ide/water gave

Claims (1)

  1. 2. 2,4-dichlorobenzamido-2-imidazoline.
US00088978A 1969-11-18 1970-11-12 Benzamidoimidazolines Expired - Lifetime US3725429A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB56271/69A GB1268259A (en) 1969-11-18 1969-11-18 Imidazoline derivatives

Publications (1)

Publication Number Publication Date
US3725429A true US3725429A (en) 1973-04-03

Family

ID=10476203

Family Applications (1)

Application Number Title Priority Date Filing Date
US00088978A Expired - Lifetime US3725429A (en) 1969-11-18 1970-11-12 Benzamidoimidazolines

Country Status (2)

Country Link
US (1) US3725429A (en)
GB (1) GB1268259A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019117592A1 (en) * 2017-12-12 2019-06-20 (주)프론트바이오 Compound of n-(9,13b-dihydro-1h-dibenzo[c,f]imidazo[1,5-a]azepine-3-yl)-2-hydroxybenzamide and 2-((9,13b-dihydro-1h-dibenzo[c,f]imidazo[1,5-a]azepine-3-yl) carbamoyl)phenyl acetate, preparation method therefor, and anti-inflammatory and analgesic agent containing same

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2584401B1 (en) * 1985-07-04 1987-11-20 Ile De France NOVEL BENZAMIDE, METHOD FOR PREPARING THE SAME, AND APPLICATION THEREOF IN THE THERAPEUTIC FIELD

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Itoh et al. Chem. Abst. Vol. 71, No. 81489g (1969, Oct. 27, 1969) QD1.A51 *
Musinu et al. Chem. Abst. Vol. 70, No. 55930d (1969). QD1.A51 *
Shibata Rubber Chem. Abst. Vol. 67, No. 82717j (1967). QD1.A51 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019117592A1 (en) * 2017-12-12 2019-06-20 (주)프론트바이오 Compound of n-(9,13b-dihydro-1h-dibenzo[c,f]imidazo[1,5-a]azepine-3-yl)-2-hydroxybenzamide and 2-((9,13b-dihydro-1h-dibenzo[c,f]imidazo[1,5-a]azepine-3-yl) carbamoyl)phenyl acetate, preparation method therefor, and anti-inflammatory and analgesic agent containing same
CN111566107A (en) * 2017-12-12 2020-08-21 先生株式会社 Compounds of N- (9,13b-dihydro-1H-dibenzo [ c, f ] imidazo [1,5-a ] azepin-3-yl) -2-hydroxybenzamide and 2- ((9,13b-dihydro-1H-dibenzo [ c, f ] imidazo [1,5-a ] azepin-3-yl) carbamoyl) phenylacetate, processes for their preparation and anti-inflammatory and analgesic agents comprising the same
US11396511B2 (en) 2017-12-12 2022-07-26 Frontbio Co., Ltd. Substituted 9,13b-dihydro-1H-dibenzo[c,f]imidazo[1,5-a]azepin-3-ylbenzamides as anti-inflammatory and analgesic agents

Also Published As

Publication number Publication date
GB1268259A (en) 1972-03-29

Similar Documents

Publication Publication Date Title
US4670566A (en) 3-methyl-hio-4-(5-, 6-, or 7-)phenylindolindolin-2-ones
US4440785A (en) Methods of using 2-aminobiphenylacetic acids, esters, and metal salts thereof to treat inflammation
US3505350A (en) Certain substituted 2-mercaptoimidazole derivatives
US3818014A (en) 2-quinolyl-4(5)-trifluoromethylimidazoles
US4225591A (en) 2,6-Diaminonebularines
US4584383A (en) Substituted 2-mercapto-imidazoles and their preparation
US3632645A (en) Substituted phenylacetyl derivatives of guanidine o-alkylisoureas s-alkylisothioureas and p-nitrobenzylisothiourea
US3775409A (en) 1,3-thiazines
US3862152A (en) 3-carbamoylamino-4-phenyl quinoline compounds
US3634508A (en) Phenylacetylguanidines
US3725429A (en) Benzamidoimidazolines
US3822262A (en) Phenyl acetylimino-imidazolines and-hexahydropyrimidines
US4113868A (en) 5,6-dihydropyrimidin-4(3h)one derivatives, and antiedema compositions and methods employing them
US3499002A (en) 1-carbamoyl-3-aroylpyrrolidines
US3574210A (en) 2,4-disubstituted-6-nitro-and 6-a minoquinazolines
US2748122A (en) 2-anilino-4, 6-dimethylpyrimidines
US4968708A (en) Imidazo[2,1-B]benzothiazole compounds and antiulcer compositions containing the same
US3740401A (en) 2-(n-cycloalkyl-phenylamino)-2-imidazolines-(2) and salts thereof
US2748124A (en) 1-(4-anilino-2-pyrimidino)-3-alkylureas
US3337539A (en) Tetraethoxy-1, 2, 3, 4-tetrahydroisoquinoline derivatives and salts thereof
US3843636A (en) 1-(5-(p-methoxyphenyl)furfurylidene)amino)hydantoin
US4333951A (en) 2-Amino-6-biphenylacetic acids
US3453286A (en) Process for preparing cycloheptimidazolinium halides
US4171367A (en) Pyrazolyl amino imidazolines
US3758491A (en) Novel anti infective agents and means of producing the same